StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Somil Mehta, Sharekhan

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: NA (inferred 1–3 months)29 Jun 2026via Zee Business (Live)

Entry₹1,381.5Stated
Target₹1,470
Total upside +6.41% (call closed)
Stop loss₹1,250-9.52% risk
Exit₹1,25010 Jul 2026, 12:07 pm
Stop-loss hit-9.52%
Follow Somil Mehta for new calls(32% target hit, 81 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 3 active Short-term calls on DRREDDYSee 39 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 11:55 pm IST
3 supporting1 opposing
Supports the BUY call (3)

5 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·10 Jul · today

Dr. Reddy's Laboratories Limited announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States.

NSE · Press Release·13 Jun · 4w ago

(opens in new tab)

Dr. Reddy's Laboratories Ltd. has launched Bosutinib Tablets 400mg.

BSE · Company Update·13 Jun · 4w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

4 advisors have active long-term SELL calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·10 Jul · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Somil Mehta, Sharekhan

Every call and its outcome